FFA
CTKB icon

Farther Finance Advisors’s Cytek Biosciences CTKB Stock Holding History

Farther Finance Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$788 Buy
176
+81
+85% +$382 ﹤0.01% 5167
2025
Q4 		$480 Hold
95
– – ﹤0.01% 5064
2025
Q3 		$330 Sell
95
-4,776
-98% -$17.9K ﹤0.01% 4626
2025
Q2 		$16.6K Buy
4,871
+1,629
+50% +$5.43K ﹤0.01% 2793
2025
Q1 		$12.7K Buy
3,242
+2,407
+288% +$12.5K ﹤0.01% 2617
2024
Q4 		$5.42K Sell
835
-30
-3% -$179 ﹤0.01% 2634
2024
Q3 		$4.79K Buy
865
+17
+2% +$96 ﹤0.01% 2662
2024
Q2 		$4.76K Buy
848
+41
+5% +$246 ﹤0.01% 2418
2024
Q1 		$5.41K Hold
807
– – ﹤0.01% 2035
2023
Q4 		$7.36K Buy
+807
New +$5.08K ﹤0.01% 1763

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Farther Finance Advisors's CTKB Position: Q1 2026 in Review

Farther Finance Advisors increased its Cytek Biosciences (CTKB) stake by 85% in Q1 2026, buying an estimated $382 and bringing the position to 176 shares worth $788. The position accounts for ﹤0.01% of the portfolio, ranked #5167.

Farther Finance Advisors first reported a position in CTKB in Q4 2023 and has held it in 10 quarters since. The position peaked at $16.6K in Q2 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Farther Finance Advisors held 176 shares of Cytek Biosciences worth $788 as of Q1 2026.
  • Farther Finance Advisors bought 81 Cytek Biosciences shares in Q1 2026, an estimated $382.
  • Cytek Biosciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q1 2026, its #5167 holding.
  • Farther Finance Advisors first reported a position in Cytek Biosciences in Q4 2023 and has held it in 10 quarters since.
  • Farther Finance Advisors's Cytek Biosciences position peaked at $16.6K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Farther Finance Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.